Urolithin A & Inflammation: What the Research Shows

Inflammation is not one thing. It is a fast, useful defense that flares and resolves, and it is a slow, low-grade hum that can settle in with age. Understanding the difference is the key to reading what the research on urolithin A actually says, and what it does not.

Two kinds of inflammation, and why the distinction matters

Acute inflammation is the body doing its job. A cut, a sprain, a passing infection, a hard training session, all of these summon immune cells, redness, swelling and warmth, and then the response winds down. That resolution is a feature, not a bug. Problems arise when a faint version of that signal never fully switches off. Researchers call this persistent, low-grade, non-resolving state inflammaging, and it becomes more common as we get older.

Inflammaging is different from the sharp inflammation of an injury. It is chronic, systemic and low in intensity, driven by a mix of accumulated cellular stress, changes in the immune system, and worn-out cellular machinery. It is measured through subtle markers in the blood rather than through obvious swelling. Because it is condition-adjacent territory, it is worth being clear from the start: nothing on this page is about treating any inflammatory disease. This is about the everyday biology of how inflammation is regulated, and the emerging structure and function research around a compound called urolithin A.

Where mitochondria enter the picture

Mitochondria are the small structures inside your cells that turn food and oxygen into usable energy. They are also deeply tied to how cells manage stress. When mitochondria become damaged and are not cleared efficiently, they can leak signals that the immune system reads as a threat, nudging cells toward a more inflammatory posture. Over years, an accumulation of these tired mitochondria is one of the threads that researchers connect to the low-grade inflammatory tone of aging.

This is where mitochondrial health becomes relevant to the inflammation conversation. The body has a built-in quality-control process called mitophagy, in which cells identify worn-out mitochondria and recycle them so fresh ones can take their place. You can read a plain-language explainer in our guide to what mitophagy is. Mitophagy tends to become less efficient with age. The scientific interest in urolithin A rests largely on its observed ability to support this recycling process.

What is urolithin A, briefly

Urolithin A is a gut postbiotic. It is not something plants make directly. Instead, your gut microbiome converts compounds called ellagitannins, found in pomegranates, walnuts and certain berries, into urolithin A. The catch is that not everyone's microbiome performs this conversion well, which is one reason a standardized supplement is of interest to researchers. For a fuller primer, see the urolithin A guide and our overview of foods high in urolithin A. In preclinical work, urolithin A has been shown to promote mitophagy, and that mechanism is the throughline connecting it to both energy and inflammation research.

The human evidence, organized by strength

Because inflammation is a sensitive topic, it is worth being precise about what has actually been tested in people versus what remains early laboratory work.

Newer human research most relevant to inflammaging

The most directly relevant human study is a 2025 randomized controlled trial published in Nature Aging (PubMed 41174221). Over roughly 28 days in midlife adults, urolithin A supported the mitochondrial health of immune cells, a finding the authors frame in the context of inflammaging. This matters because immune cells are metabolically demanding, and their mitochondrial fitness shapes how they behave. It is a promising, mechanistically coherent result, but it is one short trial, and it describes support for cellular mitochondrial health rather than a change in any disease.

A second relevant human dataset comes from an 8-week randomized controlled trial in resistance-trained men, published in the Journal of the International Society of Sports Nutrition in 2024 (doi 10.1080/15502783.2024.2419388). It examined endurance and recovery markers, which overlap with the oxidative-stress and recovery signals that surround the inflammation conversation in athletes. Again, this is structure and function research in a specific, healthy population, not a claim about inflammatory conditions.

The foundational human safety and mechanism work

The first-in-human study, Andreux et al. 2019 in Nature Metabolism, established that urolithin A was safe and well tolerated at doses up to 1,000 mg per day and produced a mitochondrial gene-expression signature in participants. It did not test inflammation as an outcome, but it is the reason later trials could use these doses with confidence. Subsequent human trials, including Liu and D'Amico et al. 2022 in JAMA Network Open (5:e2144279) in older adults and Singh et al. 2022 in Cell Reports Medicine (PubMed 35584623) in middle-aged adults, focused on muscle endurance, strength and exercise performance rather than inflammation. They are covered in our clinical studies overview. They are relevant here mainly because they reinforce the mitochondrial mechanism across multiple healthy populations.

What preclinical research is exploring

The foundational mechanism work, Ryu et al. 2016 in Nature Medicine, was done in worms and rodents. It showed that urolithin A induced mitophagy and improved muscle function in animals, and extended lifespan in C. elegans. This is important context for the mechanism, but it is animal and cell research, not proof of a human anti-inflammatory effect. Broader explorations of urolithin A in areas such as gut, skin, brain and heart biology remain in the early, preclinical stage. When you see enthusiastic claims online, this is usually the tier of evidence being stretched.

Honest limitations

A 2024 systematic review in Ageing Research Reviews, focused on targeting aging with urolithin A in humans, reached a measured conclusion: the human evidence is still emerging, the trials tend to be short, and the sample sizes are modest. That is the fair summary. Urolithin A is not an anti-inflammatory drug, it is not a substitute for one, and it should not be treated as a way to manage any inflammatory condition. If you are dealing with persistent pain, swelling, or a diagnosed inflammatory or autoimmune condition, that is a conversation for your doctor, not a supplement decision. This guide is educational and is not a treatment.

Practical guidance

If you are considering urolithin A as part of a broader routine that supports mitochondrial health, the clinically studied range is 500 to 1,000 mg per day, taken consistently. Human trials that reported benefits generally ran for weeks to months, so patience matters; see how long urolithin A takes to work. The most productive way to think about it is as one supporting input alongside the fundamentals that genuinely influence inflammatory tone: regular movement, adequate sleep, a diet rich in whole foods, and not smoking. If you want to compare formats and quality standards, our roundup of the best urolithin A gummies walks through what to look for, including third-party testing and honest dosing.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This guide is educational and is not a substitute for advice from a qualified healthcare provider.